Ocera Therapeutics (NASDAQ:OCRX)‘s stock had its “buy” rating reissued by analysts at Cowen in a report released on Monday. They currently have a $11.00 target price on the biopharmaceutical company’s stock.
OCRX has been the topic of a number of other research reports. Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a report on Saturday, August 26th. HC Wainwright lowered Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price objective on the stock. in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. Ocera Therapeutics presently has an average rating of “Hold” and an average price target of $3.55.
Ocera Therapeutics (OCRX) opened at $1.79 on Monday. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $2.95.
A hedge fund recently raised its stake in Ocera Therapeutics stock. Hikari Power Ltd raised its position in Ocera Therapeutics Inc (NASDAQ:OCRX) by 79.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 676,596 shares of the biopharmaceutical company’s stock after purchasing an additional 300,000 shares during the period. Hikari Power Ltd owned 2.55% of Ocera Therapeutics worth $771,000 at the end of the most recent quarter. 17.69% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/12/20/cowen-reiterates-buy-rating-for-ocera-therapeutics-ocrx.html.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.